
PTHS Stock Forecast & Price Target
PTHS Analyst Ratings
Bulls say
Pelthos Therapeutics is in a very strong financial position, with $24 million in cash, access to additional funds, and three FDA-approved products in its commercial portfolio. With Zelsuvmi quickly becoming the market leader in the treatment of MC and strong adoption and utilization, Pelthos is well-positioned for success in the biopharmaceutical market. The company's focus on both commercial operations and research and development adds diversity to its revenue streams, and its solid IP protection and partnership with Horizon add stability to its financials. Overall, Pelthos has the potential for significant growth and a bright future ahead.
Bears say
Pelthos Therapeutics is experiencing robust growth with record product revenue and strong performance of Zelsuvmi marked by high prescriber adoption, improved access, and positive real-world feedback. However, a limited commercial adoption for Ycanth, high lesion burden subsets, and procedure limitations for dermatologists pose challenges. In the near-term, the focus is on Zelsuvmi launch execution, but potential future indications across dermatology offer potential for continued growth.
This aggregate rating is based on analysts' research of Pelthos Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PTHS Analyst Forecast & Price Prediction
Start investing in PTHS
Order type
Buy in
Order amount
Est. shares
0 shares